The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled "Amgen v. Sandoz: What Now?" on September 2, 2015 from 2:00 to 3:00 pm (ET). Krista Carver of Covington & Burling; Kevin Nelson of Duane Morris; and Elizabeth Weiswasser of Weil, Gotshal & Manges LLP will discuss:
• Branded company strategy now that an innovator may have only six months notice before a biosimilar launch; the implications of having no information about the biosimilar maker’s patent strategy or manufacturing process; the new importance of competitive intelligence;
• Biosimilar launch strategy, including the pros & cons of the BPCIA pathway – will any biosimilar aspirants still choose to go the BPCIA route?; the importance of due diligence and assessing at-risk launches;
• New litigation dynamics outside the BPCIA, including crucial preliminary injunction battles, discovery, licensing, damages and willfulness; and
• The next front and the end game: en banc at the Federal Circuit? How will this all end up?
The registration fee for the webinar is $130 (government and academic rates are available upon request). Those interested in registering for the webinar can do so here.
Comments